Pelthos Therapeutics Inc (PTHS) Stock Price, Quote & News

Company Profile

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indi...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 908 2400

Website: pelthos.com

Address:

4020 Stirrup Creek Drive, Suite 110, Durham, United States

Jwa68 May. 27 at 12:31 AM

$PTHS Half off sale still. Management executing. Deep value.

0 · Reply

Dave2468999077844 May. 22 at 6:15 PM

$PTHS what is this filing? https://www.sec.gov/Archives/edgar/data/1919246/000195917326003914/xsl144X01/primary_doc.xml

0 · Reply

Jwa68 May. 20 at 11:14 PM

$PTHS Under the radar, still deep value. Management executing

0 · Reply

twib May. 19 at 8:09 PM

$PTHS Slowly working its way back to 30. Nice little trend from 20. Hanging tight.

0 · Reply

MarketBeat May. 16 at 12:13 AM

https://marketbeat.com/a/8657178/ $PTHS Pelthos Therapeutics Q1 Earnings Call Highlights

0 · Reply

Jwa68 May. 15 at 1:28 PM

$PTHS Oppenheimer ups to 66 from 62.

1 · Reply

Jwa68 May. 14 at 7:42 PM

$PTHS Nice volume. Slowly grinding up. Undervalued.

0 · Reply

EarningsInsider May. 14 at 1:30 PM

https://www.marketbeat.com/earnings/reports/2026-5-14-pelthos-therapeutics-inc-stock/ $PTHS Pelthos Therapeutics Earnings Transcript

0 · Reply

StocktwitsEarnings May. 14 at 12:27 PM

$PTHS Q1 '26 Earnings Results & Recap Pelthos Therapeutics Inc. reported a net loss of $10.24M and total revenue of $10.91M for the three months ended March 31, 2026. The company had $31.98M in cash and cash equivalents.

0 · Reply

mateo86 May. 13 at 9:59 PM

$PTHS ER must have missed.... Jesus what a swing in price today

1 · Reply

Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

May 15, 2026, 8:14 PM EDT - 15 days ago

Pelthos Therapeutics Q1 Earnings Call Highlights

2026-05-15T11:43:25.000Z - 15 days ago

Pelthos Therapeutics price target raised to $66 from $62 at Oppenheimer

2026-05-14T12:40:10.000Z - 16 days ago

Pelthos Therapeutics reports Q1 EPS ($3.58), consensus ($3.09)

May 14, 2026, 8:30 AM EDT - 16 days ago

Pelthos Therapeutics Earnings Call Transcript: Q1 2026

May 14, 2026, 8:30 AM EDT - 16 days ago

Pelthos Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:30 AM EDT - 16 days ago

Pelthos Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 16 days ago

Pelthos Therapeutics Announces First Quarter 2026 Financial Results

May 13, 2026, 7:00 AM EDT - 17 days ago

Pelthos Therapeutics Slides: Corporate presentation

May 1, 2026, 8:30 AM EDT - 4 weeks ago

Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026

Apr 13, 2026, 7:00 AM EDT - 6 weeks ago

Pelthos Therapeutics Slides: Corporate presentation

2026-04-10T21:05:40.000Z - 7 weeks ago

Pelthos Therapeutics says John Gay to succeed Francis Knuettel II as CFO

2026-04-01T11:03:03.000Z - 2 months ago

Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-04-01T10:05:12.000Z - 2 months ago

Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-03-31T14:21:12.000Z - 2 months ago

Pelthos Therapeutics doses first patient in CT2000 trial

Mar 31, 2026, 8:30 AM EDT - 2 months ago

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Mar 23, 2026, 6:00 PM EDT - 2 months ago

Pelthos Therapeutics Transcript: The 38th Annual Roth Conference

2026-03-23T15:15:22.000Z - 2 months ago

Pelthos Therapeutics Inc trading resumes

2026-03-23T15:10:12.000Z - 2 months ago

Pelthos Therapeutics Inc trading halted, volatility trading pause

2026-03-20T11:35:30.000Z - 2 months ago

Pelthos Therapeutics price target raised to $62 from $60 at Oppenheimer

Mar 19, 2026, 8:00 AM EDT - 2 months ago

Pelthos Therapeutics Earnings Call Transcript: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 2 months ago

Pelthos Therapeutics Annual report: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 2 months ago

Pelthos Therapeutics Earnings release: Q4 2025

2026-03-19T10:35:13.000Z - 2 months ago

Pelthos Therapeutics reports Q4 EPS ($6.87) vs. ($3.19) last year

Mar 19, 2026, 6:30 AM EDT - 2 months ago

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Mar 19, 2026, 6:00 AM EDT - 2 months ago

Pelthos Therapeutics Slides: Corporate presentation

Mar 12, 2026, 8:30 AM EDT - 2 months ago

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

2026-02-27T10:05:51.000Z - 3 months ago

Pelthos Therapeutics initiated with an Overweight at Piper Sandler

Feb 26, 2026, 10:00 AM EST - 3 months ago

Pelthos Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-26T00:55:12.000Z - 3 months ago

Pelthos Therapeutics price target lowered to $55 from $57 at Roth Capital

2026-02-02T21:50:24.000Z - 4 months ago

Pelthos Therapeutics files $200M mixed securities shelf

Feb 2, 2026, 7:00 AM EST - 4 months ago

Pelthos Therapeutics Registration statement: Registration Filing

2026-01-26T13:26:13.000Z - 4 months ago

Pelthos Therapeutics price target raised to $60 from $57 at Oppenheimer

2026-01-15T21:15:23.000Z - 4 months ago

Horizon Technology provides $50M loan facility to Pelthos Therapeutics

HRZN

Jan 15, 2026, 4:10 PM EST - 4 months ago

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

HRZN

2026-01-13T13:50:50.000Z - 4 months ago

Pelthos Therapeutics secures up to $50M senior secured term loan

HRZN

Jan 13, 2026, 8:30 AM EST - 4 months ago

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Jan 12, 2026, 7:00 AM EST - 4 months ago

Pelthos Therapeutics Slides: Corporate presentation

2026-01-05T12:35:38.000Z - 5 months ago

Pelthos Therapeutics acquires Xeglyze topical treatment for $1.8M

Jan 5, 2026, 7:30 AM EST - 5 months ago

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

Dec 4, 2025, 9:30 AM EST - 6 months ago

Pelthos Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-04T12:05:10.000Z - 6 months ago

Pelthos signs benefit manager agreement expanding patient access to ZELSUVMI

2025-12-03T14:05:36.000Z - 6 months ago

Lake Street starts Pelthos with a Buy on ‘category-leader potential’

2025-12-03T13:15:27.000Z - 6 months ago

Pelthos Therapeutics initiated with a Buy at Lake Street

Nov 25, 2025, 7:00 AM EST - 6 months ago

Pelthos Therapeutics Proxy statement: Proxy Filing

Nov 14, 2025, 7:00 AM EST - 7 months ago

Pelthos Therapeutics Proxy statement: Proxy Filing

Nov 13, 2025, 8:00 AM EST - 7 months ago

Pelthos Therapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

Pelthos Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

Pelthos Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 6:45 AM EST - 7 months ago

Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results

Nov 7, 2025, 8:00 AM EST - 7 months ago

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

Nov 5, 2025, 8:00 AM EST - 7 months ago

Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025

Oct 12, 2025, 7:00 AM EDT - 8 months ago

Pelthos Therapeutics Slides: Corporate Presentation

Sep 19, 2025, 8:00 AM EDT - 9 months ago

Pelthos Therapeutics Registration statement: Registration Filing

Sep 8, 2025, 8:30 AM EDT - 9 months ago

Pelthos Therapeutics to Participate in Upcoming September Investor Conferences

Aug 28, 2025, 8:00 AM EDT - 9 months ago

Pelthos Therapeutics Registration statement: Registration Filing

Aug 18, 2025, 8:00 AM EDT - 10 months ago

Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update

Jwa68 May. 27 at 12:31 AM

$PTHS Half off sale still. Management executing. Deep value.

0 · Reply

Dave2468999077844 May. 22 at 6:15 PM

$PTHS what is this filing? https://www.sec.gov/Archives/edgar/data/1919246/000195917326003914/xsl144X01/primary_doc.xml

0 · Reply

Jwa68 May. 20 at 11:14 PM

$PTHS Under the radar, still deep value. Management executing

0 · Reply

twib May. 19 at 8:09 PM

$PTHS Slowly working its way back to 30. Nice little trend from 20. Hanging tight.

0 · Reply

MarketBeat May. 16 at 12:13 AM

https://marketbeat.com/a/8657178/ $PTHS Pelthos Therapeutics Q1 Earnings Call Highlights

0 · Reply

Jwa68 May. 15 at 1:28 PM

$PTHS Oppenheimer ups to 66 from 62.

1 · Reply

Jwa68 May. 14 at 7:42 PM

$PTHS Nice volume. Slowly grinding up. Undervalued.

0 · Reply

EarningsInsider May. 14 at 1:30 PM

https://www.marketbeat.com/earnings/reports/2026-5-14-pelthos-therapeutics-inc-stock/ $PTHS Pelthos Therapeutics Earnings Transcript

0 · Reply

StocktwitsEarnings May. 14 at 12:27 PM

0 · Reply

mateo86 May. 13 at 9:59 PM

$PTHS ER must have missed.... Jesus what a swing in price today

1 · Reply

JFais May. 13 at 1:58 PM

$PTHS $22 to $28 move since posted thesis (NP)

2 · Reply

twib May. 13 at 5:14 AM

$PTHS I hate to cross post but it so slow here...anyway, do some dd on SLS! 2 great drugs imo with one(gps) trial due anyday now(tmrw til maybe 2 mo timespan)and the 2nd destroys the common binary nature of bios by being a 1st in class imo cdk9 inhibitor in trials showing no adverse reactions/safety concerns and solid efficacy. **No rev bio so play safely**

1 · Reply

Jwa68 May. 13 at 2:10 AM

$PTHS Progress over perfection. Target in the low $40's with continued execution.

0 · Reply

twib May. 12 at 9:52 AM

$PTHS What, premarket movement? Prob only 2 shares but i dont kniw if I've seen that b4. 👀🤔

0 · Reply

SuperGreenToday May. 12 at 3:33 AM

$PTHS

0 · Reply

twib May. 12 at 1:00 AM

$PTHS Boring but I'll tske our slow rise from $20.Im curious to see what kinda vol they get if put up with a decent er.

0 · Reply

Jwa68 May. 11 at 8:47 PM

$PTHS Nice day. Still half off sale. Boring but great management and execution.

0 · Reply

twib May. 11 at 6:43 PM

$PTHS Prob end the day with 8x avg vol! Small but someone smart said its all relative. Getting ready for er boost imo!🤞

0 · Reply

twib May. 11 at 7:57 AM

$PTHS Read may 14th next er! Thats this thurs. 🤞👍

0 · Reply

Jwa68 May. 6 at 11:42 AM

$PTHS Still...

1 · Reply

JFais Apr. 28 at 4:13 PM

$PTHS (NP) Breaking out last couple days Perhaps too low volume for the Core Biotech portfolio, but I shared this one in our most recent Playbook post (potential setups on radar) Hat tip to @plainyogurt21 for flagging

0 · Reply

Jwa68 Apr. 27 at 10:17 PM

$PTHS Still very undervalued.

1 · Reply

Market Cap	92.00M
Revenue (ttm)	16.80M
Net Income (ttm)	-43.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-257.86%
Debt to Equity Ratio	0.75

Volume	10,300
Avg Vol	17,902
Day's Range	N/A - N/A
Shares Out	3.48M
Stochastic %K	56%
Beta	3.29
Analysts	Strong Sell
Price Target	$57.71